** Shares of Virpax Pharmaceuticals VRPX.O fall 10.4% to 50 cents premarket
** Late on Friday, co disclosed it had received notice on Nov. 19 from Nasdaq about non-compliance with independent director and audit committee rules
** Co says it has appointed Esha Randhawa as an independent director and audit committee member; adds that it has regained compliance with listing rule
** Plans to notify Nasdaq of its compliance - VRPX
** As of last close, stock had fallen 82.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。